A must-read for patients with BRAF mutations: Trametinib’s latest efficacy, medication key points and price analysis

In 2025, the field of precision cancer treatment will continue to heat up. At the latest annual meeting of the American Society of Clinical Oncology (ASCO), multiple long-term follow-up data on trametinib (Trametinib) combined with dabrafenib (Dabrafenib) were released, once again attracting great attention from the global oncology community. This "BRAF+MEK" dual-target combination regimen not only consolidates its first-line status in the treatment of melanoma, but also shows encouraging efficacy in cancer types driven by BRAF mutations such as non-small cell lung cancer (NSCLC).

01 ASCO Annual Meeting Focus: "BRAF+MEK" program significantly prolongs survival

At the ASCO 2025 annual meeting, the long-term follow-up results of multiple clinical trials including COMBI-AD and COMBI-APlus were announced. These studies mainly evaluated the therapeutic effect of trametinib combined with dabrafenib in patients with BRAF V600 mutation-positive melanoma. The results showed:

5 year recurrence-free survival rate (RFS): trametinib+dabrafenib adjuvant treatment group was 52%, while the placebo group was only 36%;

Overall survival rate (OS): 5 years of follow-up showed that the median OS in the combination group has not yet been reached, while that in the control group was 78 months, and the survival benefit was significant;

The risk of recurrence was reduced by 53%, demonstrating durable disease control.

In the population with advanced unresectable melanoma, the combination regimen also performed well. COMBI-vThe results of the study showed that compared with vemurafenib alone, the combination of trametinib+dabrafenib improved the median OS from 17.2 months to 25.6 months, and the complete response rate increased from 8% to 19%.

Researchers pointed out that this combination can effectively delay the occurrence of drug resistance through the double attack of "front blockage BRAF and backblock MEK", making the targeted treatment effect more lasting.

02 Interpretation of the mechanism of action: Dual target blockadeMAPK pathway

Trametinib is a highly selective and reversible MEK1/2 inhibitor that is an oral small molecule targeted drug. Its core mechanism is to block the MEK kinase activity in the MAPK signaling pathway, thereby inhibiting the proliferation and survival of tumor cells.

BRAF mutations can lead to continued abnormal activation of the MAPK pathway. Although traditional BRAF inhibitors can inhibit signaling in the short term, they soon develop resistance due to reactivation of downstream MEK. The combination of trametinib and BRAF inhibitors (such as dabrafenib) can achieve "upstream and downstream linkage blockade" and has the following advantages:

Precise inhibition of dual targets to delay drug resistance;

Rapidly reduce tumor volume, suitable for patients with heavy burden;

The overall side effects are controllable, it can be administered orally, and it is highly convenient.

03 Indications continue to expand: from melanoma to non-small cell lung cancer

▶ 1. Melanoma (Melanoma)

Trametinib combined with dabrafenib is the first-line standard treatment for BRAF V600 mutation-positive unresectable or metastatic melanoma. International guidelines clearly recommend this combination, which is not only suitable for advanced patients, but has also been approved for adjuvant treatment, significantly reducing the risk of postoperative recurrence.

▶ 2. Non-small cell lung cancer (NSCLC)

In BRAF V600E mutation-positive NSCLC patients, the combination of trametinib + dabrafenib has also been FDA approved for use in previously treated advanced patients. Clinical data show that the objective response rate (ORR) reaches 64%, and the median progression-free survival time (P FS) for more than 10 months, providing an effective targeted solution for a small number of BRAF mutated lung cancer patients.

▶ 3. Exploration of other tumor types

Currently, trametinib is also conducting multiple clinical trials in colorectal cancer, thyroid cancer, cholangiocarcinoma, etc.BRAF mutated solid tumors. Preliminary results show that combination therapy is expected to expand its clinical landscape.

04 Clinical research data are eye-catching, and international guidelines strongly endorse it

Based on the above studies, NCCN, ESMO, CSCO and other national guidelines list trametinib+dabrafenib as BRAF Standard treatment for patients with V600mutated melanoma andNSCLC.

05 Side Effects and Management Measures

The adverse reactions of trametinib mainly come from its inhibition of the MEK pathway. Common side effects include:

1.Fever (up to 50%) usually occurs 1-2 weeks after combined medication, and can be controlled by antipyretics and short-term discontinuation of medication;

2.Skin rash, diarrhea, and fatigue are mostly mild to moderate;

3. Decreased cardiac function and retinopathy require regular echocardiography and eye examinations;

4.Elevated liver enzymes and hematological abnormalities.

5.Fever and skin reactions are most common when combined with BRAF inhibitors, but are generally manageable. It is clinically recommended to closely monitor body temperature and cardiac function in the early stages of medication. If adverse reactions of grade ≥ 3 occur, the dose may be suspended or reduced.

06 Price Information and Drug Purchase Channels

At present, trametinib has been officially launched in China and is included in medical insurance.

0.5mg×30 tablets: The latest price is about three to four thousand yuan;

2 mg

Laotian generic drugs: have been approved for sale by the local Ministry of Health. The price is about more than 1,000 yuan, and the ingredients are basically the same as the original drugs. They are an economic alternative for some patients.

It is recommended that patients give priority to purchasing drugs through regular domestic hospital pharmacies or pharmaceutical companies with legal qualifications to avoid the risks of informal purchases.

07 Medical Insurance and Future Prospects

Trametinib has been included in the national medical insurance directory, which greatly reduces the financial burden on patients. As "BRAF+MEK" combination therapy becomes increasingly popular in clinical use in China, it is expected that more domestic generic drugs will be approved in the future and prices will further drop.

In addition, with the advancement of exploration of combined immunization and triple regimen (targeted +targeted +immunization), the application potential of trametinib in advanced melanoma and other BRAF mutated cancer types will be further expanded.

Trametinib, as a representative drug of MEK inhibitors, forms a "double sword" with the BRAF inhibitor dabrafenib, creating a new era of precision treatment in BRAF mutation-related cancers. From prolonging survival to adjuvant therapy to reduce the risk of recurrence, to expanding its application in lung cancer and other tumors, trametinib is gradually becoming the backbone of global cancer treatment. With medical insurance coverage and the launch of generic drugs, its "efficiency +accessibility" advantages will benefit more Chinese patients.

xa0

References:

1.ASCO Annual Meeting 2025. https://meetings.asco.org

2.COMBI-v Trial. N Engl J Med 2015; 372:30–39.

3.COMBI-AD Trial. N Engl J Med 2017; 377:1813–1823.

4.NCCN Guidelines – Melanoma & NSCLC 2024. https://www.nccn.org

5.National Medical Products Administration (NMPA) official website: https://www.nmpa.gov.cn